Plain-English translation of NCT06241599 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new drug called AK104 combined with chemotherapy to see if it can help patients whose nasopharyngeal cancer (a type of throat cancer) has come back or spread to other parts of the body after their first treatment. About half of the 300 participants will receive the medication along with chemotherapy, while the other half will receive a placebo (a dummy infusion) along with the same chemotherapy. Researchers want to know if this treatment improves survival and how safe it is.
When nasopharyngeal cancer returns or spreads after initial treatment, it becomes much harder to treat and patients have limited options. This medication works differently than standard chemotherapy — it helps the body's own immune system fight the cancer — so researchers believe combining it with chemotherapy might give patients better chances of survival.
You likely qualify if…
You likely don't qualify if…
You will visit a hospital or research center regularly to receive intravenous infusions (through an IV in your arm) of either the new medication or a placebo, combined with standard chemotherapy drugs. Each infusion takes at least an hour. You will also have blood tests and imaging scans (like CT scans) to check how well the treatment is working and to monitor for side effects. The study involves multiple visits over several months, with the exact schedule determined by your treatment plan.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China